Israel’s Teva has launched in the US the generic equivalent to Gleevec (imatinib mesylate) for the treatment of leukemia and other cancer-related diseases. Also, Europe has approved Teva’s CINQAERO (reslizumab) – the first intravenous anti-IL-5 biologic therapy for severe eosinophilic asthma.

http://www.tevapharm.com/news/teva_announces_launch_of_generic_gleevec_tablets_in_the_united_states_08_16.aspx

http://www.tevapharm.com/news/european_commission_grants_marketing_authorization_for_teva_s_cinqaero_reslizumab_08_16.aspx